Cargando…
A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study
Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can...
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981807/ https://www.ncbi.nlm.nih.gov/pubmed/35379309 http://dx.doi.org/10.1186/s13045-022-01259-7 |
| _version_ | 1784681677596917760 |
|---|---|
| author | Tsubata, Yukari Hotta, Takamasa Hamai, Kosuke Furuya, Naoki Yokoyama, Toshihide Saito, Ryota Nakamura, Atsushi Masuda, Takeshi Hamaguchi, Megumi Kuyama, Shoichi Honda, Ryoichi Senoo, Tadashi Nakanishi, Masamoto Yamasaki, Masahiro Ishikawa, Nobuhisa Fujitaka, Kazunori Kubota, Tetsuya Kobayashi, Kunihiko Isobe, Takeshi |
| author_facet | Tsubata, Yukari Hotta, Takamasa Hamai, Kosuke Furuya, Naoki Yokoyama, Toshihide Saito, Ryota Nakamura, Atsushi Masuda, Takeshi Hamaguchi, Megumi Kuyama, Shoichi Honda, Ryoichi Senoo, Tadashi Nakanishi, Masamoto Yamasaki, Masahiro Ishikawa, Nobuhisa Fujitaka, Kazunori Kubota, Tetsuya Kobayashi, Kunihiko Isobe, Takeshi |
| author_sort | Tsubata, Yukari |
| collection | PubMed |
| description | Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01259-7. |
| format | Online Article Text |
| id | pubmed-8981807 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89818072022-04-06 A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study Tsubata, Yukari Hotta, Takamasa Hamai, Kosuke Furuya, Naoki Yokoyama, Toshihide Saito, Ryota Nakamura, Atsushi Masuda, Takeshi Hamaguchi, Megumi Kuyama, Shoichi Honda, Ryoichi Senoo, Tadashi Nakanishi, Masamoto Yamasaki, Masahiro Ishikawa, Nobuhisa Fujitaka, Kazunori Kubota, Tetsuya Kobayashi, Kunihiko Isobe, Takeshi J Hematol Oncol Letter to the Editor Management of cancer-associated venous thromboembolism (VTE) is essential in treatment selection and cancer prognosis. However, to date, there is no method to assess the risk of VTE specifically associated with advanced lung cancer. Our aim was to create a new risk assessment scoring system that can predict the concomitant or incidence of VTE in advanced lung cancer. We used the dataset of 1008 patients with lung cancer in the Rising-VTE/NEJ037 study, of which 100 (9.9%) developed VTE. The items extracted in the multivariate analysis included female sex, adenocarcinoma, performance status, N factor, lymphocyte count, platelet count, prothrombin fragment 1 + 2, and diastolic blood pressure. This model had a maximum score of 8 points, with ≥ 5 points indicating a high risk of VTE. This simple risk-assessment model for VTE complications with advanced lung cancer could help identify cases that required monitoring for VTE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01259-7. BioMed Central 2022-04-04 /pmc/articles/PMC8981807/ /pubmed/35379309 http://dx.doi.org/10.1186/s13045-022-01259-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Letter to the Editor Tsubata, Yukari Hotta, Takamasa Hamai, Kosuke Furuya, Naoki Yokoyama, Toshihide Saito, Ryota Nakamura, Atsushi Masuda, Takeshi Hamaguchi, Megumi Kuyama, Shoichi Honda, Ryoichi Senoo, Tadashi Nakanishi, Masamoto Yamasaki, Masahiro Ishikawa, Nobuhisa Fujitaka, Kazunori Kubota, Tetsuya Kobayashi, Kunihiko Isobe, Takeshi A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study |
| title | A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study |
| title_full | A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study |
| title_fullStr | A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study |
| title_full_unstemmed | A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study |
| title_short | A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study |
| title_sort | new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981807/ https://www.ncbi.nlm.nih.gov/pubmed/35379309 http://dx.doi.org/10.1186/s13045-022-01259-7 |
| work_keys_str_mv | AT tsubatayukari anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hottatakamasa anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hamaikosuke anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT furuyanaoki anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT yokoyamatoshihide anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT saitoryota anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT nakamuraatsushi anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT masudatakeshi anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hamaguchimegumi anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT kuyamashoichi anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hondaryoichi anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT senootadashi anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT nakanishimasamoto anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT yamasakimasahiro anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT ishikawanobuhisa anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT fujitakakazunori anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT kubotatetsuya anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT kobayashikunihiko anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT isobetakeshi anewriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT tsubatayukari newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hottatakamasa newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hamaikosuke newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT furuyanaoki newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT yokoyamatoshihide newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT saitoryota newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT nakamuraatsushi newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT masudatakeshi newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hamaguchimegumi newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT kuyamashoichi newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT hondaryoichi newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT senootadashi newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT nakanishimasamoto newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT yamasakimasahiro newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT ishikawanobuhisa newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT fujitakakazunori newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT kubotatetsuya newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT kobayashikunihiko newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy AT isobetakeshi newriskassessmenttoolforvenousthromboembolisminadvancedlungcanceraprospectiveobservationalstudy |